Tempus AI enters September with a striking split personality: the stock fell 9.4% on the week to $62.27, yet analysts are rushing to raise targets and a major short-covering wave has quietly unfolded beneath the surface.
The short side tells the more interesting story right now. Bears have been retreating steadily. Short interest dropped 12.8% over the past week to 15.9% of the free float — still elevated in absolute terms, but the direction of travel is unmistakable. A month ago, short interest was above 33 million shares; it has since fallen to around 27.5 million. Borrow costs reflect the same de-escalation: the cost to borrow has eased roughly 15% on the week to just 0.51%, down 26% over the past month. Availability has also loosened sharply, reaching 152% — up from a tight range below 50% that persisted through late July and early August. The borrow market is no longer anywhere near stressed, even as the short interest percentage remains high. Positioning looks less like a reinforcing bear conviction and more like an orderly exit.
Options traders tell a slightly more cautious tale. The put/call ratio ticked up to 0.39 — the highest reading of the past two weeks and nearly two standard deviations above the 20-day mean of 0.36. That is still well below the 52-week high of 0.66, so this is not panic hedging. But the mild uptick in put demand, coinciding with a week when the stock gave back 9%, suggests some investors are buying protection after the recent 42% one-month run-up. The ORTEX short score has eased slightly to 68 from a recent high of 73, consistent with the short-covering narrative rather than new pressure building.
The Street is leaning clearly bullish, making the week's price decline look more like profit-taking than a fundamental reassessment. Cantor Fitzgerald initiated coverage with an Overweight rating and an $80 target. Piper Sandler upgraded from Neutral to Overweight, lifting its target from $56 to $76. BTIG had already raised its Buy target to $80 in mid-August. The consensus points to around $66.73, modest upside from the current price, but the more recent top-end targets cluster in the $75-$80 range — implying roughly 20-29% from here if that view prevails. The bull case rests on AI-driven oncology data, a differentiated real-world dataset, and a personalized cancer vaccine program. Bears counter with a high cash burn, regulatory uncertainty, and valuation that remains stretched: the EV/EBITDA multiple is above 112x, and the price-to-book has climbed to 24x over the past month as the stock ran hard. The forward earnings momentum factor ranks in just the 5th percentile on a 90-day basis — estimate revisions have been moving against the stock even as the price surged.
The ownership picture carries a nuance worth noting. CEO Eric Lefkofsky sold roughly $1.9 million of stock on August 25 across multiple transactions, all conducted under a pre-arranged 10b5-1 plan. Director Nadja West also sold $207,000 on August 28, also via plan. Planned sales carry considerably less signal than discretionary ones, but the timing — during a month when the stock rallied 42% — is at least consistent with insiders using elevated prices to reduce exposure. Lefkofsky remains the dominant holder at around 22.8% of shares outstanding. ARK Investment Management has been a buyer, adding roughly 415,000 shares through July. Franklin Templeton added over 770,000 shares in the same period, and Citadel built a position of nearly 1.9 million shares. Activist-style 13D filings are absent — all registered large holders file passive 13G schedules. Stakes are as last disclosed around the 5% threshold, and holders falling below that level may not refile.
The prior two earnings prints are the other thread worth watching. The most recent report on July 30 produced a 5.6% one-day gain and an 11% five-day move. The August 4 print showed a 1.4% day-one move and a 20.9% five-day move. The next event is scheduled for October 30. Between now and then, the question is whether the short-covering trend continues to compress the 15.9% float short — and whether analyst upgrades can stabilise a stock that gave back nearly a third of its month-long rally in a single week, while a sector-wide drawdown in genomics and life-science tools pulled peers like PACB and TXG down 15.8% and 7.3% respectively over the same period.
See the live data behind this article on ORTEX.
Open TEM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
